RBC Capital reiterated $CLYM Outperform-$23.
[ $JBIO $OTSKY VRTX RHHBY ARGX BIIB VERA TVTX ]
RBC Capital said in its note: Our nephrologist survey shows strong initial enthusiasm for APRIL/BAFFs, with utilization of these drugs likely to grow significantly over the next 2-3 years (supporting an ~$8B penetration-adjusted U.S. market).
While efficacy and eGFR data likely drive initial choice, our data suggests that dosing convenience could become more important over time, and we think potential for Q12W dosing from drugs like '116 can capture ~$1B in out-year sales, balancing increasing competition in the space (JBIO, Otsuka, and VRTX).
CLYM shares have sold off considerably (-45%) in the last several months and are trading well below the ~$12/share that we think could be supported by the IgAN oppty alone.
With considerable de-risking data next year from '116 (NAVIGATE-2 ph.Il data and potential initiation of a pivotal trial) and other pipeline optionality from budoprutug across PMN, ITP, and SLE serving as a backstop for shares, we would continue to be buyers.
BRiley reiterated $CLYM Buy-$30 after recently hosting an investor breakfast in London.
[ $RHHBY $VRTX ARGX BIIB VERA TVTX JBIO ]
BRiley said--We recently hosted an investor breakfast in London with Buy-rated CLYM ($30 PT), where group discussion questions centered most heavily on (1) the steps that take CLYM116 in IgAN and budoprutug in pMN into Ph3 in 2027,
(2) how budos PMN data compare with RHHBYs (NR) newly approved Gazyva, and
(3) what to expect from budo outside the kidney, in ITP and lupus.
For the renal-centric thesis, we note the differentiation on dosing interval and target is well established, so value creation from here depends on execution, i.e., NAVIGATE-2 patient data and FDA end-of-Ph2 feedback in 1H27 for CLYM116, and higher-dose PrisMN data that set budos Ph3 dose (10/25 ASN26 Kidney Week recap).
The upside surprise TAM expanding indications represents budos exploration in ITP and lupus, which adds nicely to a catalyst-rich roadmap. Specifically, budos ITP update at ASH on 12/13 comes in a late-line setting, where approved orals deliver a durable response in about 1 in 5 patients.
Its first lupus signal compares well with recent peer data. Comparator events fill the same window, i.e., VRTXs (NR) povetacicept PDUFA date on 11/30, ARGXs (NR) third ITP Ph3 for Vyvgart, and BIIBs (NR) twin lupus Ph3 readouts this quarter.
We believe EV of ~$500M (fully diluted) heavily discounts two kidney programs with pivotal starts possible next year, before any credit for ITP or lupus.
1
812
Guggenheim⬆️ $GHRS's PT to $46, reiterated Buy and said--We caught up with GHRS management after 3Q26 and are encouraged that the pivotal design is largely set, with initiation planned for 2027.
[ $JNJ $LLY - ATAI DFTX CMPS HELP ]
Final HV-106 results support moving GH001 (inhaled mebufotenin, a short-acting psychedelic for TRD) from the Phase IIb individualized dosing regimen (up to three titrated doses per visit) to a single fixed dose on the proprietary Aerosol Delivery System (ADS), giving every patient the same ~1-hour visit and simplifying clinic scheduling and billing, if approved.
Management described FDA interactions as constructive, with protocol alignment rather than design changes left for the 1Q27 EOP2 meeting. The company plans two TRD pivotals enrolled in parallel, each double-blind vs. placebo, with a fixed dose on Day 1 and a re-treatment before the Week 4 primary endpoint, closely mirroring Phase IIb. As-needed dosing will continue through a 12-week blinded period, which management views as consistent with the FDA's July 2026 guidance. CMC and device plans were covered at a Type C meeting, with only IND updates remaining. Recall Phase IIb delivered a -15.5 point placebo-adjusted MADRS reduction at Day 8, 57.5% Day 8 remission vs. 0% on placebo, and 73% remission at 6 months among OLE completers, still the most robust short-term efficacy in TRD, in our view. The ~1-hour visit, vs. at least 2 hours for Spravato (JNJ) and 6-8+ hours for psilocybin and LSD, strengthens the session economics story. New CDO Vanina Popova, MD (ex-JNJ; lead author of the pivotal Spravato TRD publication) adds relevant experience as the company moves toward the pivotal study. A PPD pivotal is targeted for 2H27. The backdrop remains supportive (LLY/ATAI deal, DFTX Phase III data, CMPS NDA submission, HELP's positive APPROACH readout).
Reiterate Buy; PT moves to $46 from $40.
Stifel reiterated $GHRS Buy-$38 and said--GH has met with FDA and has preliminarily aligned on a ph3 design that is consistent with psychedelic guidelines.
[CMPS JNJ DFTX LLY HELP]
Most notable is that this ph3 moves away from the IDR (patient-level dose-titration) and leverages the company's next-gen inhalation device.
We caught up with management, and we believe the plan here sets GH up well to generate robust ph3 data with GH001:
(1) the next-gen device has much improved PK variability--also increasing average exposure,
(2) in turn, patient-level dose-titration is less necessary--ph3 doses will match exposure to the efficacious doses in ph2 [12/18mg], and
(3) the trials will have a 4-week primary endpoint and remain blinded to 12-weeks, but will allow for re-treatment which maximizes probability-of-success.
GH plans another meeting with FDA in 1Q, so study start (shortly after) is slightly later than expected, but net-net we see this as overall positive.
BRiley reiterated $CLYM Buy-$30 after recently hosting an investor breakfast in London.
[ $RHHBY $VRTX ARGX BIIB VERA TVTX JBIO ]
BRiley said--We recently hosted an investor breakfast in London with Buy-rated CLYM ($30 PT), where group discussion questions centered most heavily on (1) the steps that take CLYM116 in IgAN and budoprutug in pMN into Ph3 in 2027,
(2) how budos PMN data compare with RHHBYs (NR) newly approved Gazyva, and
(3) what to expect from budo outside the kidney, in ITP and lupus.
For the renal-centric thesis, we note the differentiation on dosing interval and target is well established, so value creation from here depends on execution, i.e., NAVIGATE-2 patient data and FDA end-of-Ph2 feedback in 1H27 for CLYM116, and higher-dose PrisMN data that set budos Ph3 dose (10/25 ASN26 Kidney Week recap).
The upside surprise TAM expanding indications represents budos exploration in ITP and lupus, which adds nicely to a catalyst-rich roadmap. Specifically, budos ITP update at ASH on 12/13 comes in a late-line setting, where approved orals deliver a durable response in about 1 in 5 patients.
Its first lupus signal compares well with recent peer data. Comparator events fill the same window, i.e., VRTXs (NR) povetacicept PDUFA date on 11/30, ARGXs (NR) third ITP Ph3 for Vyvgart, and BIIBs (NR) twin lupus Ph3 readouts this quarter.
We believe EV of ~$500M (fully diluted) heavily discounts two kidney programs with pivotal starts possible next year, before any credit for ITP or lupus.
Piper Sandler reiterated $CLYM Overweight-$40 and said that it Believes It's a Good Time to Own Ahead of Strong Catalyst-Flow after its Virtual Group Investor Meeting Post-ASN
$VERA $TVTX JBIO RHHBY BIIB VRTX
Piper Sandler said in its note: CLYM has been unduly trading down, in our view, where investors are not appreciating the strength of CLYM116 (anti-APRIL) and budoprutug (anti-CD19) data at ASN (note).
Accordingly, we hosted CLYM for a virtual investor group meeting to walk through key aspects of their multiple presentations.
Specifically, Mabworks' (private) Ph1 HV data corroborated CLYM116's best-in-class profile where it showed up-to ~70% Gd-IgA1 reductions and has initial Ph2 NAVIGATE-2 IgAN data 1H27 (Ph3 initiation 2H27).
Moreover, budoprutug's Ph2 PrisMN initial 200 mg data recapitulated the robust B-cell and anti-PLA2R reductions observed in the Ph1b PoC and de-risks ongoing assessment of higher doses.
Importantly, budoprutug has two upcoming catalysts with Ph1b/2a ITP additional data and Ph1b global SLE initial data 4Q26. Hence, we remain bullish on CLYM and believe it is a good time to own ahead of strong catalyst-flow.
Wedbush⬆️ $RZLT's PT to $10,⬆️PoS in cHI & tHI and reiterated Outperform.
[CRNX - VRTX AMLX RYTM ZLDPF]
Wedbush said in its note: The PT increase was based on
1) a higher probability of success (PoS) for both congenital HI and tumor HI in the U.S. (from 75% to 80%),
2), higher market penetration in U.S. tumor HI patients (from reaching 18% of eligible patients in 2035 to reaching 30% of a larger eligible population), and
3) adding back to our valuation the ex-U.S. revenues for congenital HI, which we removed completely after the negative top-line data from the Ph3 sunRIZE study in Dec. '25 despite a PRIME designation that RZLT had already received from the EMA, but with a PoS of 50%.
We have also adjusted our model to reflect last week's approximately $100M capital raise, which according to management will support a runway through FDA approvals for both congenital HI and tumor HI.
With positive clinical update and a stronger balance sheet, RZLT should provide a more appealing investment opportunity, in our opinion.
JonesTrading⬆️ $RZLT's PT to $14 from $12 and reiterated at a Buy rating.
$ZLDPF $CRNX AMLX
JonesTrading said in its note:
Rezolute hosted an investor KOL event to update the Street on ersodetug's market opportunity in hyperinsulinism (presentation).
With topline Ph3 data in CHI coming in December, much of the investor questions have now shifted to the market opportunity.
On the call, KOL insights suggest that there are ~3000 initially addressable Tumor HI patients (prev. estimate was ~1500).
For CHI, we have always maintained that the addressable market will include both patients who are responsive and non-responsive to diazoxide.
All patients will likely still be offered diazoxide as 1L, but for responsive patients, ersodetug is well-positioned to address patients who do not tolerate diazoxide or those who still experience some degree of hypoglycemia (as evidenced by 40% of Ph3 patients who are on diazoxide).
We think there's still plenty of unappreciated value in ersodetug as a broad treatment for hypoglycemia, and see Rezolute as a prime take-out target for pharma looking for a bolt-on acquisition in rare disease.
Model update: Our prior estimates included 1,500 islet cell tumor patients in the US, but did not include non-islet cell tumor hypoglycemia (NICTH); including ~1,500 US NICTH patients (ex-US tbd) takes our PT to $14 from $12. Reiterate Buy & Increasing PT to $14 from $12.
829
Wells Fargo⬆️ $PRAX to Overweight-$509 from Equal Weight-$343.
[DRUG SAGE JAZZ RAPP UCBJY ESAIY OVID XENE]
Wells Fargo said in its Praxis Upgrade:
First, we were initially worried about the robustness of the primary endpoint. There are a lot of "statistical robustness" issues that we had to get comfortable with. We viewed ulixa getting BTD on the basis of Ph3 data as supportive of the endpoint change, but the lack of disclosure on the ITT prespecified sensitivity analysis, despite disclosing JTR ITT analyses, made us nervous.
We spoke with 2 statisticians after the PRAX Investor Day, and are now less worried about the robustness of the primary endpoint. PRAX disclosed additional analyses that they shared with the FDA, including the prespecified tipping point analysis (d = 2.5) on an ITT basis. Importantly, it didn't tip, and conveys a similar efficacy narrative to the mITT analysis. KOL feedback was positive, and they also felt the add'l analyses strengthen the case that ulixa's effect is real.
Secondly, we were concerned that there may not be much data to inform the FDA on the alternative titration protocol. We believe the alt. titration protocol was proposed to mitigate early discontinuations. We felt this put the FDA in a tough spot as they might have to infer any efficacy impacts to the slower titration w/o data. However, PRAX has communicated that they think it's "very likely" for the alt. protocol to be on the label. We don't know FDA's stance, but co. commentary is encouraging.
Guggenheim⬆️ $PRAX's PT and said--We reiterate our BUY rating and raise our PT to $1,050 (from $800).
[DRUG JAZZ RAPP SAGE UCBJY ESAIY OVID XENE]
At investor day, PRAX laid out a $20B+ peak sales vision across four assets.
Ulixacaltamide remains the main driver of the stock, and the case going into its 1/29/27 PDUFA got stronger.
Given that the late-cycle meeting (LCM) is already completed, we believe early approval is possible.
All four FDA-requested sensitivity analyses were statistically significant (1.41-2.59 pts on mADL11). The first long-term snapshot (n = 68) showed ADL gains doubling to ~6 points by week 95.
The field force is already deployed and management points to a ~$50K net price, so we raise our net price to $50K and our peak sales estimate to $10B.
Relutrigine: the data holds up, but we're cutting our PoS until the label is clearer. New 18-month OLE data showed ~86% seizure reduction. Still, KOLs told us a statistically significant result is what it takes for broad DEE use, which makes EMERALD topline (4Q26) the key value inflection catalyst for the asset. We have limited visibility on the label ahead of the 12/27/26 SCN2A/8A PDUFA (mgmt strikes a cautious tone on the FDA review). We therefore lower our PoS for relutrigine (SCN2A/8A 60%, broad DEE 50%) and vormatrigine (25%).
The pipeline keeps getting broader. PRAX added T-type line extensions, next-gen CaV3 molecules and a pain program (PRAX-215, Phase I), and plans a 2027 NDA for elsunersen.
1
4
1,000
RBC Capital y'day⬇️ $CGON to Sector Perform from Outperform and⬆️PT to $97 from $80.
[URGN JNJ TARA TYRA MRK IBRX]
RBC Capital said in its note: We think today's data reinforced creto's compelling efficacy and safety data, and clearly defines a large (>$4.5B) opportunity for the drug in bladder cancer.
However, with this major value inflection now behind us, we are balancing the setup against a regulatory path that may still be evolving – with some delays, potential risk on CMC, and consequently, a commercial launch that is unlikely before '28 in a space that is increasingly competitive.
So while we believe creto may be best-in-class, we think the next leg up for shares may take some time to materialize, and are moving to the sidelines with a Sector Perform rating (Spec. Risk qualifier unchanged). Price target to $97 (from $80) on model updates.
H.C. Wainwright reiterated $CGON and said --Yesterday, CG Oncology published the results of their Phase 3 BOND-003 data in high-risk BCG unresponsive NMIBC in Lancet Oncology.
$JNJ $URGN TARA TYRA MRK IBRX
H.C. Wainwright added—The data remain stalwart, with a 75.5% (95% CI 66.3-83.2) CR at any time and pristine safety profile with no Grade 3+ TRAEs, treatment-related discontinuations or deaths. Cretostimogene demonstrated a 46% (95% CI 36.8-56.1) CR at 12 months and 42% (95% CI 32.5-51.6) CR at 24 months, both consistent with KM estimates of 50.7% and 42.4% respectively. The 12- and 24-month duration of response was 64.2% (95% CI 52.2-73.8) and 60.1% (95% CI 48.2-70.0), respectively, with a mDOR of at least 27.9.
These data remain extremely competitive with Inlexzo (JNJ, not rated) with clear safety and administration advantages.
Beyond the headlines, we focus on some of the underappreciated aspects of BOND-003's data that underscore core pillars of our investment thesis. We reiterate our Buy rating and $100 PT.
1
955
Guggenheim⬆️ $PRAX's PT and said--We reiterate our BUY rating and raise our PT to $1,050 (from $800).
[DRUG JAZZ RAPP SAGE UCBJY ESAIY OVID XENE]
At investor day, PRAX laid out a $20B+ peak sales vision across four assets.
Ulixacaltamide remains the main driver of the stock, and the case going into its 1/29/27 PDUFA got stronger.
Given that the late-cycle meeting (LCM) is already completed, we believe early approval is possible.
All four FDA-requested sensitivity analyses were statistically significant (1.41-2.59 pts on mADL11). The first long-term snapshot (n = 68) showed ADL gains doubling to ~6 points by week 95.
The field force is already deployed and management points to a ~$50K net price, so we raise our net price to $50K and our peak sales estimate to $10B.
Relutrigine: the data holds up, but we're cutting our PoS until the label is clearer. New 18-month OLE data showed ~86% seizure reduction. Still, KOLs told us a statistically significant result is what it takes for broad DEE use, which makes EMERALD topline (4Q26) the key value inflection catalyst for the asset. We have limited visibility on the label ahead of the 12/27/26 SCN2A/8A PDUFA (mgmt strikes a cautious tone on the FDA review). We therefore lower our PoS for relutrigine (SCN2A/8A 60%, broad DEE 50%) and vormatrigine (25%).
The pipeline keeps getting broader. PRAX added T-type line extensions, next-gen CaV3 molecules and a pain program (PRAX-215, Phase I), and plans a 2027 NDA for elsunersen.
Raymond James reiterated $PRAX Strong Buy-$945 and said--We continue to view Praxis as one of the most compelling setups in SMID biotech, with the next few months offering multiple opportunities to unlock the value of what we believe could become two multi-billion-dollar CNS franchises.
[DRUG JAZZ RAPP SAGE UCBJY ESAIY OVID XENE]
Our deep dive (link) into relu's mechanism, breadth of preclinical evidence, and EMERALD's heterogeneity risk leaves us constructive on both the probability of Ph3 success and the magnitude of its commercial opportunity.
Separately, our due diligence (link) on ulixa's clinical and regulatory package, including its statistical considerations and regulatory precedent, underpins our high conviction in approval at the January 29 PDUFA.
We are encouraged by management's commercial readiness, with relu's commercial organization fully hired and ulixa's field-force buildout progressing ahead of potential launches.
Taken together, we believe Praxis is approaching a transformational stretch, with a catalyst-rich outlook, substantial commercial upside, and a balance sheet that positions the company to execute from a position of strength.
TD Cowen reiterated $HALO Buy-$130 and said--Recent Volatility Presents A Buying Opportunity - Bear Thesis Thinner Than Ever
[TAK RHHBY JNJ ARGX LLY ORKA BMY PFE VRTX GSK ABBV GMAB CHGCY ABOS SKYE TEVA]
HALO's recent pullback is fundamentally disconnected from the underlying royalty outlook.
Final CMS guidance confirms what we already knew, current valuation overly conservative on commercial ENHANZE products + treats entire pipeline as upside (13 launches in '29-'32, Hypercon, Aerocon, Keytruda).
Thus, this reset is an attractive entry point ahead of significant value unlock over the next 18 mos.
H.C. Wainwright reiterated $HALO Buy-$130 and said -- Switching Takeda's primary immunodeficiency patients from GAMMAGARD LIQUID or CUVITRU to TAK-881 could add Halozyme royalties.
$TAK $RHHBY JNJ ARGX LLY ORKA BMY PFE VRTX GSK ABBV GMAB CHGCY ABOS SKYE TEVA
H.C. Wainwright added — On October 14, Takeda (TAK; not rated) presented detailed Phase 2/3 IgGNITE results for its investigational 20% subcutaneous immunoglobulin (SCIG) with Halozyme's recombinant human hyaluronidase (ENHANZE) in primary immunodeficiency (PID). Median single-site infusions took 75.8 vs. 132 minutes with HYQVIA, a 42.6% reduction; two-site infusions took 58.3 vs. 86 minutes, a 32.2% reduction. The same IgG dose required half the volume, with dosing every three to four weeks.
We think these gains could retain HYQVIA patients and attract patients from Takeda's own non-ENHANZE GAMMAGARD LIQUID and CUVITRU, expanding Halozyme's royalty base even with flat Takeda immunoglobulin sales.
811
William Blair🏁 $STIM at an Outperform rating.
[BWAY NPCE LIVN MDT BSX [CMPS JNJ GHRS HELP ATAI - LLY DFTX]]
William Blair said in its initiation report: STIM has begun a positive transition. Under new senior leadership, Neuronetics has initiated several new strategies in 1H26 that have delivered positive early results.
STIM's core NeuroStar transcranial magnetic stimulation (TMS) system is now being offered through more flexible purchasing models, opening up new customer segments previously untapped.
And at the company's Greenbrook network of psychiatry clinics, focused efforts are underway to drive better efficiency, profitability, and cash generation.
In the first two quarters of these initiatives (along with a broader cost savings program), sales growth has been solid (~11% YOY in 2Q/3Q26) and adjusted EBITDA has improved meaningfully ($2M in 2Q/3Q vs -$10M in the same period last year). At ~1x EV/sales, the shares do not reflect the underlying improvements or new drivers ahead. We initiate coverage at Outperform.
BRiley🏁 $STIM and said -- We are initiating coverage of Neuronetics, Inc. (STIM) with a Buy rating and $5 price target (~70% upside), following the late-2024 Greenbrook acquisition and management reset in 2026.
BWAY NPCE LIVN MDT BSX
$CMPS $JNJ GHRS HELP ATAi - LLY DFTX
BRiley added—We believe Greenbrook's revenue growth and operating leverage may translate disproportionately into earnings, thereby supporting a revaluation of STIM from a levered TMS device company to a scaled interventional psychiatry platform.
Importantly, Greenbrook provides organic mid teens growth and substantial unused capacity while also positioning STIM to benefit from a psychedelic-driven shift in interventional psychiatry.
This transformation coincides with accelerating commercial adoption, payer acceptance, and specialist training, driving a new wave of interventional psychiatry.
Covenant resolution and sustained positive adjusted EBITDA should support a higher multiple for the dual-device/services platform; STIM trades at ~1.5x FY28E EV/sales versus ~2.4x for blended peers.
Our $5 price target reflects normalization toward that benchmark, with minimal contribution from psychedelics, where potential COMP360 approval in 1H27E and a string of subsequent approvals across the category could justify a premium multiple.
1
940
Cantor reiterated an Overweight rating on $LXEO and said--One-time gene therapy LX2020's showing of 80% mean reduction in non-sustained ventricular tachycardia (NSVT) far exceeds the ~30% provided by current pharmacological standard of care and what we believe to be the market's bar-and significantly derisks eventual accelerated approval as we anticipate this measure to be the primary endpoint of the upcoming pivotal study.
[TYNA RCKT [BIIB LRMR PTCT DSGN SLDB NBIX VYGR]]
Safety with high dose LX2020 presented no surprises.
Together with LX2006, in pivotal development for Friedreich ataxia, we see LXEO as possessing two assets that each offer line of sight to $1B+ sales potential for unmet patient populations that are genetically-defined and clinically-identifiable.
We had already viewed the shares as trading at a significant discount to the FA opportunity alone; today's news appears to put that discount into even sharper relief. We are buyers.
Cantor reiterated $LXEO Overweight-$35 and said that it Sees a High PoS for the FA Pivotal Trial (2H27 guide) hitting on Deepened Conviction.
[BIIB LRMR PTCT]
Cantor said in its note:
Topline data from SUNRISE-FA 2, the pivotal trial evaluating LX2006 (AAVrh10-based gene therapy) for Friedreich's ataxia (FA), are guided for 2H27 and represent a major upcoming catalyst for LXEO shares.
Investor debate has centered on the PoS of this trial, particularly given that the trial is powered around a >= 15% LVMI treatment effect, while a ≥10% threshold is considered clinically meaningful.
Lexeo has conducted analyses supporting a ~99% probability of achieving ≥15% effect size informed by the Phase 1/2 data and additional natural-history and CLARITY-FA data not available to the public.
This has prompted us to go a step further and independently assess the trial's PoS and deepen our conviction ahead of the readout.
The punchline is that our analysis also supports a high PoS for the pivotal trial, increasing our conviction ahead of this major catalyst.
BTIG reiterated $JBIO Buy-$77 and said--JBIO continues to execute as multiple key catalysts approach, with the Phase 3 (EVERGREEN) trial of JADE101 in IgAN expected to initiate later in 4Q26 and the ongoing Phase 2 (JUNIPER) trial expected to deliver interim data in 2Q27.
[ $OTSKY TVTX VERA VRTX [ $PFE ROIV AZN ARGX [NVS BIIB - RHHBY AMGN]]]
We continue to view IgAN as an attractive >$20B market opportunity (~170k U.S. patients) where strong early VOYXACT commercial results further support our view that anti-APRIL therapies are likely to command preferential use. JADE101 could potentially differentiate through deeper IgA suppression, favorable PK/PD supporting infrequent Q12W maintenance dosing, and a cleaner MoA vs. APRIL+BAFF inhibition.
In dermatomyositis (DM), JADE301 targets IFN-, a mechanism that has been clinically de-risked by dazukibart. In preclinical studies JADE301 showed greater potency vs. a dazukibart comparator and an extended half-life, supporting its potential for a best-incategory profile and infrequent dosing via SC administration. A Phase 1 trial of JADE301 in HVs is expected to initiate in 4Q26, with interim data anticipated in 2H27.
The Phase 1 trial of JADE201 in rheumatoid arthritis is ongoing, with interim biomarkerrich data expected in 2027 to inform indication prioritization.
Wedbush reiterated $JBIO Outperform-$47 after the Co. reported preliminary preclinical data for JADE301 at EADV and remained on track to kick off a Phase 1 healthy volunteer study in 4Q26.
$PFE $ROIV AZN ARGX
OTSKY TVTX VERA VRTX NVS
Wedbush said in its note: Preclinical JADE301 data demonstrates ~3x longer half-life vs. dazukibart (PFE, not covered). Additionally, the JADE301 SC and IV doses demonstrated similar time/concentration profiles. Phase 1 results will better inform on human dosing and safety.
Bottom line, we see the initial data appearing supportive.
No change to our JBIO estimates as we continue to leave JADE301 as upside to our estimates.
We look ahead to 2027 as an important turning point for JBIO with multiple readouts lining up including initial JUNIPER Phase 2 JADE101 data.
Wedbush reiterated $EPRX Outperform-$17 and provided its Upside/downside scenario for the Co's upcoming readout.
[REGN - SNY TAK PHAT TRAX AZN AMGN BMY]
Wedbush said in its note: EPRX emphasized percent changes in histologic and endoscopic endpoints due to milder histologic scores at baseline. We accordingly add relevant parameters to our scenario analysis, and reiterate expectations of ~$17 upside and ~$5 downside (Fig. 1-3).
We emphasize the interim analysis is not powered for statistical significance, and that EoE endpoints generally do not correlate in historical trials. Although prescribers will likely weigh outcomes across all endpoints including dysphagia (DSQ, SDI), histology (EoEHSS, PEC), and endoscopy (EREFS), we speculate patients will be most concerned with dysphagia improvement.
RBC Capital🏁 $EPRX and said--We are initiating coverage of Eupraxia Pharmaceuticals with an Outperform, Speculative Risk rating and $14.00 PT.
[REGN - SNY PHAT TRAX BMY ABBV]
Eupraxia is a clinical-stage biotech developing EP-104GI, a once-yearly submucosal injection that pairs a well-characterized, FDA-approved corticosteroid (fluticasone propionate) with a first-in-class extended-release delivery platform (DiffuSphere), sustaining near-constant esophageal drug levels for 9-12 months from a single endoscopic administration.
The target indication, eosinophilic esophagitis, is projected to affect ~1MM Americans (2030E).
With open-label Ph1b/2a data demonstrating ~80% symptomatic remission, a clean safety profile, and a vehicle-controlled Ph2b interim readout expected in Dec-2026, we believe EPRX offers an asymmetric risk/ reward with meaningful upside.
1
897
Stifel reiterated $GHRS Buy-$38 and said--GH has met with FDA and has preliminarily aligned on a ph3 design that is consistent with psychedelic guidelines.
[CMPS JNJ DFTX LLY HELP]
Most notable is that this ph3 moves away from the IDR (patient-level dose-titration) and leverages the company's next-gen inhalation device.
We caught up with management, and we believe the plan here sets GH up well to generate robust ph3 data with GH001:
(1) the next-gen device has much improved PK variability--also increasing average exposure,
(2) in turn, patient-level dose-titration is less necessary--ph3 doses will match exposure to the efficacious doses in ph2 [12/18mg], and
(3) the trials will have a 4-week primary endpoint and remain blinded to 12-weeks, but will allow for re-treatment which maximizes probability-of-success.
GH plans another meeting with FDA in 1Q, so study start (shortly after) is slightly later than expected, but net-net we see this as overall positive.
Cantor⬆️ $GHRS's PT to $35 from $25, reiterated Overweight and said: With a $1.5B mkt cap, we believe GHRS trades at <1x peak achievable sales for '001.
$JNJ HELP ATAI CYBN DFTX $CMPS
Canaccord Genuity y'day reiterated GH Research Buy; $39 and said: GHRS reported its 1Q26 results earlier today (5/14). Operating expenses of $18.7mn were essentially in line with our $19.0mn estimate.
The key updates for us were that GHRS has selected its doses for a global Phase 3 pivotal program.
Importantly, the company reiterated its intent to seek FDA alignment on Phase 3 trial design for GH001 (inhaled mebufotenin or 5-MeO-DMT) for treatment-resistant depression (TRD), and remains on track to start a global Phase 3 program in late 2026.
Separately, with the lifting of the FDA hold, which now seems like a distant memory, the company has completed enrollment in its Phase 1 trial (GH001-HV-109) in the US in healthy volunteers.
With a recent raise, and typical prudence and discipline in its spending, we view GHRS as well capitalized to carry out its plans.
On the stock, our thesis remains the same, i.e., we still view GHRS as significantly undervalued at current levels, as GH001 checks important boxes for a short duration in the clinic, rapid/durable efficacy, and solid safety so far in TRD.
As a reminder, TRD is a large indication with significant unmet need, and we continue to believe that space exists for multiple approaches/ products. Reiterate BUY.
Wedbush🏁 $MTRI and said--We are initiating coverage of Mentari Therapeutics (MTRI) at an Outperform rating and $33 target.
[HLUBF HLBBF $INM ]
Simply put, we see MTRI's strategic focus on developing a suite of migraine therapies as unique and competitively differentiating. We see both MT-001 (anti-PACAP) and MT-002 (bispecific PACAP/CGRP) holding blockbuster potential as PACAP appears to be an orthogonal migraine target that can complement CGRP. The rise of CGRP-targeted agents shifted the standard of care in migraine and expanded prevention treatment with the overall class annualizing to >$6B in revenue.
Nevertheless, roughly half of CGRP-treated patients fail to achieve a 50% or greater reduction in monthly migraine days, underscoring the need for novel treatments.
Our base case ($33 target) assumes MT-001 and MT-002 reach the market in FY33 and FY34, respectively, with FY35 total revenue reaching $1.36B. We see a favorable risk/reward setup with shares trading in the high-teens and cash (~$9/sh) providing downside protection. Upside unlocks with pipeline expansion and/or increased commercial uptake.
938
BTIG⬆️ $OBIO's PT to $12 and reiterated Buy after Orchestra BioMed hosted its R&D Day in New York City and virtually.
[MDT OTSKY CVRX BSX ABT TRUMY JNJ PHG BDX SZSE TFX]
BTIG said in its note: We came away with a newfound appreciation for the clinical differentiation of OBIO's atrioventricular interval modulation (AVIM) therapy, the clear commercial appeal, and the broader potential in heart failure. More detail on the Virtue SAB program underscored clinicians' interest in a treatment that does not leave anything behind in the vessel and improves clinical outcomes for the challenging in-stent restenosis population. We think the differentiation of the Virtue SAB technology will translate to better efficacy.
A recurring theme of the discussions during the event was the interest in studying potential applicability to larger, underserved patient populations.
We are encouraged by OBIO's progress with its existing programs.
We raise our outyears estimates for adoption of both AVIM and Virtue SAB therapy but believe our forecasts are still conservative, as they only contemplate U.S. commercialization and do not assume either full adoption of AVIM therapy or market share gains as a result. This event gives us greater confidence in our forecasts.
We raise our PT from $10 to $12, based on a 6.5x EV/Sales multiple on our 2034 sales estimate with a 10% discount rate. Reiterate Buy.
Piper Sandler reiterated $OBIO Overweight-$12 and said -- We wanted to highlight OBIO as a name that could drive significant value creation for shareholders in the coming quarters.
$MDT LGND TRUMY
$CVRX BSX
Piper Sandler added—Its key AVIM therapy to treat hypertension patients recently completed enrollment in its pivotal trial, with a data release in Q2'27 (likely HRS).
If positive,
which we believe it will be,
it could lead to approval for this unique therapy in early '28 (though we believe the stock will move on the data).
AVIM revenue (global) to OBIO could amount to $37M in '28 revenue and potentially $130M in '30. With little operating expenses associated with the model, EBIT could be $68M by the end of the decade.
For MDT, AVIM could allow them to charge significantly more for their pacemakers and potentially contribute ~70 bps or more to top-line growth in the coming years.
We believe investors should start to look at and build positions in OBIO. Reiterate OW.
2
994
Wells Fargo🏁 $DNLI and said--We think we are approaching an inflection point w/ TfR technology given the approval of Avlayah, constructive FDA feedback on Zafi, & validating data from Roche's tronti in AD. Commercial assets provide a floor, see upside w/ AD. Initiate OW, PT $35.
[PRTA IONS BCYC $RHBBY [TAK RGNX RARE SGMOQ [ESAIY - BIIB LLY ]]]
DNLI has validated TfR technology with broad applicability.
DNLI has pioneered transferrin receptor (TfR) technology with one FDA approved product, Avlayah (Hunter Syndrome).
We now think DNLI is in a position to capitalize on their platform and accelerate drug development.
We think expected cash flows from Avlayah, and soon zafi (Sanfilippo), provide a floor value to the stock, and expect advancement of assets in development in bigger markets (Alzheimer's disease) to re-rate shares higher.
Morgan Stanley, in a broad research note earnings preview, ⬆️ $ASND to $275 from $256, reiterated (reit'd) Overweight; $DNLI to $36 from $35, reit'd Overweight; $EXEL to $53 from $50, reit'd Equal Weight; and $INCY to $104 from $103, reit'd Equal Weight, and said 2Q26 earnings should reinforce a shift from macro-driven trading toward stock-specific execution and differentiation.
1
722
Citizens reiterated $SGMT Market Outperform-$27 and said--Following the strategic pivot to acne earlier this year, SGMT has been firing on all cylinders with growing excitement for denifanstat's opportunity in acne.
[ $ASCLF GALDY DRMA BHC BFRI [MDGL LLY NVO ALGS VKTX ]]
We think AURORA has a high probability of success based on Ascletis' Phase 3 success and evaluation of the same denifanstat dose in a similar population, with the same endpoints but with substantially greater powering (~800 patients randomized 2:1 vs. 480 patients randomized 1:1).
The Phase 3 data will come relatively fast, which we think will continue SGMT's share strength through next year.
Phase 2 data from next-gen FASN inhibitor TVB-3567 next year should at least extend IP coverage for SGMT and, at best, provide a differentiated option for patients. We consider TVB-3567 as upside to our valuation, while we assign 85% POS on denifanstat and model peak WW sales of >$2.5B.
Cantor (y'day) keeps $SGMT at Overweight,⬇️risk-adj'd NPV to $25.1 from $26.4 on the larger share count and said that y'day's update is in line with its expectations.
$ASCLF $GALDY DRMA
MDGL IV LLY NVO ALGS VKTX
Cantor said -- Three-quarters of patients completed the extension: completers saw total and inflammatory lesion counts fall by ~75% and ~80%, respectively, from the ASC40-303 baseline.
Safety remained clean: no permanent discontinuations for adverse events and no drug-related serious adverse events.
Over the 52 weeks, treatment-related dry skin ran at ~7% and dry eye at ~6%.
A ~$115M gross offering: ~8.75M shares at $10/sh plus pre-funded warrants for ~2.75M shares, led by Commodore Capital and other notable funds
Today's update is in line with our expectations. We maintain our Overweight rating; our risk-adjusted NPV moves to ~$25.1/sh from ~$26.4/sh on the larger share count.
896
Cantor reiterated $LXEO Overweight-$35 and said that it Sees a High PoS for the FA Pivotal Trial (2H27 guide) hitting on Deepened Conviction.
[BIIB LRMR PTCT]
Cantor said in its note:
Topline data from SUNRISE-FA 2, the pivotal trial evaluating LX2006 (AAVrh10-based gene therapy) for Friedreich's ataxia (FA), are guided for 2H27 and represent a major upcoming catalyst for LXEO shares.
Investor debate has centered on the PoS of this trial, particularly given that the trial is powered around a >= 15% LVMI treatment effect, while a ≥10% threshold is considered clinically meaningful.
Lexeo has conducted analyses supporting a ~99% probability of achieving ≥15% effect size informed by the Phase 1/2 data and additional natural-history and CLARITY-FA data not available to the public.
This has prompted us to go a step further and independently assess the trial's PoS and deepen our conviction ahead of the readout.
The punchline is that our analysis also supports a high PoS for the pivotal trial, increasing our conviction ahead of this major catalyst.
Oppenheimer reiterated $LXEO Outperform-$20 and said--Updated LX2006 data strengthen our conviction in this candidate's market potential in Friedreich ataxia (FA).
[BIIB LRMR PTCT SLDB [TNYA RCKT]]
The neurologic efficacy signal has been extended with a 4.26-point mFARS advantage versus propensity-matched natural-history controls over two years and greater than four-point improvement from baseline in participants followed for three years.
Alongside sustained cardiac improvements, these findings increasingly support a differentiated, multisystem treatment profile over merely a cardiomyopathy-only proposition.
While small, open-label datasets require confirmation, we believe the growing consistency and durability of benefit strengthen LX2006's investment case and warrant greater recognition of its potential value.
LX2020's reveal in PKP2-ACM remains on track for this quarter-which we believe could raise this program's visibility among investors given $1B+ peak sales potential.
We see at compelling entry point in LXEO stock at current levels.
What happens to $NVDA if it comes out that the Chinese Spy was able to attain trade secrets from the Jensen Huang affair??
1
2
903
Citizens reiterated $SPRB Market Outperform-$143.
[DNLI RGNX RARE BMRM IVA]
Citizens, next Wednesday (11/18) at 1:30 ET, will host Dr. Cara O'Neill to discuss the unmet need in Sanfilippo syndrome type B (MPS IIIB).
Spruce plans on submitting its BLA for its enzyme replacement therapy (TA-ERT) in December for MPS IIIB, and as such Citizens believe it's a great time to better understand the unmet need for the neurodegenerative condition with no approved therapies today.
B | RILEY on $SPRB in a note to investors said -- We reiterate our Buy rating and $160 PT on Spruce Biosciences (SPRB) after hosting a recent vNDR with CEO Javier Szwarcberg, M.D., M.P.H., and President and CFO Samir Gharib.
$DNLI RGNX $RARE BMRN IVA
B | RILEY added — Execution and valuation have decoupled heading into the 4Q26 BLA, a gap we view as unsustainable.
Since February's FDA alignment on the accelerated approval framework, SPRB has hit every regulatory milestone, completing its first PPQ batch and clearing two pre-BLA meetings.
Over the same period, the regulatory tape turned more constructive with Denali's (DNLI - Buy, $35 PT) AVLAYAH approval in MPS II (3/25 note), the FDA's June walk-back on Regenxbio's (RGNX, NR) RGX-121, and Ultragenyx's (RARE, NR) 9/17 FAYUVI full approval in MPS IIIA (9/24 note).
Four NDR debates could re-rate the shares into the 4Q26 BLA.
First, an ex-BioMarin and ex-RARE bench is hardening a dual-path BLA; accelerated approval remains the base case, but full-approval odds have risen.
Second, atypical FDA CMC flexibility on PPQ timing signals an engaged agency looking to approve.
Third, patient finding points to a pool above Street framing with >3K MPS IIIB patients globally.
Fourth, potential novel biomarker data at WORLD in February could strengthen the efficacy case.
Yet shares are -46% YTD (vs. XBI +29%), leaving an EV of ~ $50M against our ~$200M PRV-implied floor, which RARE's voucher reinforces.
Catalysts include the BLA submission and Transform (NCT07579910) initiation (4Q26), the Songdo pre-license inspection (~YE26), WORLD data (February), Investor Day (~1Q27), and potential U.S. approval and launch (mid-27), followed by ex-U.S. expansion.
2
1,208

